Human Study of LPS Treatment
As the dosage of LPS treatment increased, the protein levels evident in the human subjects also increased making the data a positive correlation. The data confirms that there is a statistical significance between the amount of LPS treatment taken and protein levels. We chose to do an unpaired ANOVA test for the human study because more than 2 treatment levels were being compared. The p-value determined by the ANOVA test was 1.4x10^-16, which is considerably smaller than the p-value of 0.05 that is needed to confirm statistical significance. Therefore, we concluded that there is a statistical significance that when the dosage of LPS treatment is increased from 0mg to 15mg in 5mg increments, the protein levels measured also increased.
Rat Study of LPS Treatment
As the dosage of LPS treatment increased, the protein levels evident in the rats decreased making the data a negative correlation, however, the standard deviations for these two data sets were so large that no real correlation can be inferred. We chose to do an unpaired t-test on the rat sample data because only two different dosages were being compared. The p-value obtained by this test was 0.867, which is larger than 0.05, meaning that the findings on dosage of LPS treatment with the protein levels in rats was not statistically significant.
Summary/Discussion
Overall, the human study showed more positive results, and therefore more of a positive correlation. This experiment was geared more towards human due to the dosage sizes vs. weight/ body size of the subject intaking the LPS treatment. Also, the metabolism of rats is extremely high compared to humans. The medication will break down faster in the rats system (because they metabolize the drug faster) than the human system. Based off of the human results, the more of the medication the better of the results. All in all, we conclude that the drug is effective in humans at 15mg.
BME 100 Fall 2014
